May 3, 2023
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2023. Key highlights include: Net sales of $73.9 million in Q1 2023 increased 9% year-over-year on a reported basis and 11% year-over-year on a constant currency basis. Glaucoma net sales of $56.2
Go to Source
Author: